A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals

Status: Completed

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)

Study type: Observational

Funder types: Industry

Identifiers

NCT01770951

C09-001r

Details and patient eligibility

About

The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.

Enrollment: 30 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female patients of any age who have been diagnosed with aHUS.
2. Received at least one dose of eculizumab for the treatment of aHUS between 2007 and 2009 outside of an Alexion sponsored controlled clinical trial.

Exclusion criteria

1. Patients who have participated or are currently participating in a controlled clinical trial of eculizumab